Chinook Therapeutics®  Acquired by Novartis (NASDAQ:NVS)

This clinical-stage biotechnology company develops precision medicines for kidney disease. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. In 2020, Aduro Biotech – founded in 2001 by Triton to explore cancer therapies enabled by Triton’s research – was acquired by Chinook. In a subsequent transaction with Van Herk Investments, a leading European life-sciences investor, Chinook created a new company called Sairopa to pursue non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform.

Chinook’s lead program is atrasentan, a Phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a Phase 1B trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small-molecule LDHA inhibitor for treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases.

Chinook is building its pipeline by leveraging insights in kidney single-cell RNA sequencing, human-derived organoids, and new translational models to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

Sensera® Limited (ASX:SE1)

Formed in 2017 to commercialize Triton’s research, Sensera designs and manufactures specialized high-performance sensors and modules, particularly in microelectromechanical systems (MEMS) technologies. For instance, a sensor can continuously and accurately monitor blood pressure during complex surgical procedures. Abiomed (NASDAQ:ABMD) was an early adopter of this technology, as part of its Impella ® heart pump platform that allows the heart to rest and recover by improving blood flow and/or temporarily assisting with pumping functions.

SI2 Technologies Inc. (Privately Held)

This Triton spinoff focuses on the design and manufacture of flexible, high-precision antennas, arrays, and signal-management products for military air, land, sea, and space applications that face space, weight, power, and signature restrictions. It employs conventional and patented digital-printing and laser-transfer manufacturing technology to fit expansive communications gear into tight and unusually shaped spaces and surfaces.

Nanotron (acquired by Inpixion – NASDAQ: INPX)

This company’s patented technologies capture, interpret, and visualize indoor data to make indoor spaces smarter, safer, and more secure. The roots of this technology stretch back to Triton’s programs in asset tracking, which led Sensera to acquire Nanotron in 2018. Its ultrawideband (UWB), short-range RF technology detects the location of people, devices, and assets with superior precision using billions of pulses sent every couple of nanoseconds to accurately sense the location of anything that is “tagged.” UWB-enabled devices pinpoint a transmitting device, such as another smartphone or asset-tracking tag, find its precise location, and enable location-aware communication and services. While Triton developed this technology for use primarily in defense and security, especially in “GPS challenged” environments, Nanotron’s devices can be used for corporate and industrial security, asset tracking and optimization, and improved operations across many industries.

Respiri® Limited (ASX:RSH)

Thanks to Triton-developed technology, Respiri (formerly iSonea) has transformed from a medical-device company to an e-health SaaS leader that helps patients and physicians monitor and manage asthma, which affects an estimated 340 million people worldwide. Respiri’s wheezo™ offers a secure, cloud-based health platform to measure, record, and assist with asthma monitoring